The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

A 46% premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with Astellas Pharma’s Veozah.

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...